The Effect of Antenatal Nifedipine Administration on Patent Ductus Arteriosus

Öz

Aim: In his study, we aimed to determine the effect of antenatal nifedipine application on haemodynamicaly significant PDA hsPDA in very low birth weight VLBW premature infants.Material and Methods: We retrospectively evaluated the medical records of very low birth weight VLBW infants between January 2013 and December 2016.The demographic and clinical characteristics of the infants were recorded. The preterms included in the study were divided into two groups as with hsPDA and without hsPDA. Demographic, clinical features and nifedipine administration were compared between two groups.Results: A total of 602 VLBW infans were included. Two hundred fifty-seven 42.7% infants had hsPDA, and 11 1.8% of them treated with PDA ligation. The rate of administration of antenatal nifedipine in the hsPDA group was significantly higher than the rate of antenatal nifedipine administration in the non-hsPDA group . %46,7 vs %31,3; p

Anahtar Kelimeler

• Patent ductus arteriosus,premature,very low birth weight,nifedipine

Antenatal Nifedipin Kullanımının Patent Duktus Arteriozusa Etkisi

Öz

Amaç: Çalışmamızda çok düşük doğum ağırlıklı ÇDDA prematürelerde antenatal nifedipin uygulanmasının hemodinamik anlamlı patent duktus arteriozus haPDA üzerine etkisini belirlenmesi amaçlanmıştır.Gereç ve Yöntemler: Çalışmamızda Ocak 2013 ile Aralık 2016 tarihleri arasında ünitemizde izlenen, ÇDDA bebekler retrospektif olarak incelendi. Bebeklerin demografik ve klinik özellikleri kayıt edildi. Çalışmaya dahil edilen prematürelerin haPDA’sı olan ve olmayanlar olarak iki gruba ayrılarak, demografik, klinik özellikleri ve antenatal nifedipin uygulanması açından karşılaştırıldı.Bulgular: Toplam 602 ÇDDA bebeğin dahil edildiği çalışmamızda, 257 bebekte %42,7 haPDA saptandı ve 11 hastaya %1,8 PDA ligasyonu uygulandı. Hemodinamik anlamlı PDA grubunda antenatal nifedipin uygulanma oranı, haPDA olmayan gruptaki antenatal nifedipin uygulanma oranına göre istatistiksel olarak anlamlı yüksek tespit edildi %46,7 ve %31,3; p

Anahtar Kelimeler

• Patent duktus arteriozus,prematüre,çok düşük doğum ağırlığı,nifedipin

Kaynakça

1. Prescott S, Keim-Malpass J. Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options. Adv Neonatal Care 2017; 17:10-18.
2. Bhat R, Das UG. Management of patent ductus arteriosus in premature infants. Indian J Pediatr 2015; 82:53-60.
3. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010;125: 1020-30.
4. Halil H, Tayman C, Cakır U, Buyuktiryaki M, Serkant U, Oğuz SS. Serum Endocan Level as a Predictive Marker for Hemodynamically Significant Patent Ductus Arteriosus in Very Low Birth Weight İnfants. Am J Perinatol 2017; 34:1312-1317.
5. McGuirl J, Arzuaga B, Lee BH. Antenatal calcium channel blocker exposu- re and subsequent patent ductus arteriosus in extremely low-birth-weight infants. Pediatr Cardiol 2012; 33:60-4.
6. Oncel MY, Erdeve O. Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus. World J Clin Pediatr 2016; 5:75-81.
7. Hong Z, Hong F, Olschewski A, Cabrera JA, Varghese A, Nelson DP, et al. Role of store-operated calcium channels and calcium sensitization in nor- moxic contraction of the ductus arteriosus. Circulation 2006; 114:1372-9.
8. del moral T, Gonzalez-Quintero VH, Claure N, Vanbuskirk S, Bancalari E. Antenatal exposure to magnesium sulfate and the incidence of patent du- ctus arteriosus in extremely low birth weight infants. J Perinatol 2007; 27:154-7.

9. Katayama Y, Minami H, Enomoto M, Takano T, Hayashi S, Lee YK. Antena- tal magnesium sulfate and the postnatal response of the ductus arteriosus to indomethacin in extremely preterm neonates. J Perinatol 2011; 31:21- 4.
10. Guclu S, Saygili U, Dogan E, Demir N, Baschat AA. The short-term effe- ct of nifedipine tocolysis on placental, fetal cerebral and atrioventricular Doppler waveforms. Ultrasound Obstet Gynecol 2004; 24:761-5.
11. Dargaville PA, Gerber A, Johansson S, et al. Incidence and Outcome of CPAP Failure in Preterm Infants. Pediatrics 2016;138. pii: e20153985.
12. Leal YA, Álvarez-Nemegyei J, Lavadores-May AI, Girón-Carrillo JL, Cedil- lo-Rivera R, Velazquez JR. Cytokine profile as diagnostic and prognostic factor in neonatal sepsis. J Matern Fetal Neonatal Med 2018:1-7.
13. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003; 23:451-6.
14. International Committee for the Classification of Retinopathy of Prematu- rity. The International Classification of Retinopathy of Prematurity revisi- ted. Arch Ophthalmol 2005; 123:991-999.
15. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529-34.
16. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decision based upon clini- cal staging. An Surg 1978; 187: 1-7.
17. Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz SS, et al. Oral pa- racetamol versus oral ibuprofen in the management of patent ductus ar- teriosus in preterm infants: a randomized controlled trial. J Pediatr 2014; 164:510-4.e1.
18. Moore P, Brook MM. Patent Ductus Arteriosus and aorticopulmonary win- dow. Ic: Moss and Adams’ Heart Disease. Allen HD, Driscoll DJ, Shaddy RE, Feltes TF (eds). 8th ed. Philadelphia, ABD: Wolters Kluwer- Lipincott Williams& Wilkins, 2013:722- 745.
19. Köksal N, Aygün C, Uras N. Türk Neonatoloji Derneği. Prematüre Bebekte Patent Duktus Arteriosus’a Yaklaşim Rehberi 2016.
20. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventingmortality and morbidity in preterm infants. Cochrane Data- base Syst Rev 2010; (7): CD000174.
21. Philips JB, Garcia-Pratz JA, Fulton DR, Kim MS. http://www.uptodate. com/contents/ management of patent ductus arteriosus in preterm in- fants.
22. Vick GW, Satterwhite C, Cassady G, Philips J, Yester MV, Logic JR. Radi- onuclide angiography in the evaluation of ductal shunts in preterm infants. J Pediatr 1982; 101:264-8.
23. Clyman RI, Ballard PL, Sniderman S. Prenatal administration of beta- methasone for prevention of patient ductus arteriosus. J Pediatr 1981; 98:123-6.
24. Ferguson JE, Dyson DC, Schutz T, Stevenson DK. A comparison of tocoly- sis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. Am J Obstet Gynecol 1990163(1 Pt 1): 105-11.
25. Koks CA, Brölmann HA, de Kleine MJ, Manger PA. A randomized com- parison of nifedipine and ritodrine for suppression of preterm labor. Eur J Obstet Gynecol Reprod Biol 1998; 77:171-6.
26. Papatsonis DN, Kok JH, van Geijn HP, Bleker OP, Adèr HJ, Dekker GA. Ne- onatal effects of nifedipine and ritodrine for preterm labor. Obstet Gynecol 2000; 95:477-81.
27. Tsatsaris V, Papatsonis D, Goffinet F, Dekker G, Carbonne B. Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis. Obstet Gy- necol 2001; 97(5 Pt 2):840-7.
28. Oei SG. Calcium channel blockers for tocolysis: a review of their role and safety following reports of serious adverse events. Eur J Obstet Gynecol Reprod Biol 2006; 126:137-45.